Derm-Biome Pharmaceuticals

Derm-Biome Pharmaceuticals is a preclinical biopharmaceutical company developing novel topical therapies for inflammatory skin diseases, precancerous conditions, and non-melanoma skin cancers. Their lead compounds have demonstrated anti-inflammatory, antioxidant, antimicrobial, and antitumor properties in preclinical models. Notably, DB‑007‑04 has shown efficacy in inhibiting C. acnes in acne models and improving disease scores in atopic dermatitis without observable side effects or irritation. DB‑006 has shown the ability to prevent progression from precancerous lesions to squamous cell carcinoma in UV-induced mouse models[6].